TNFSF14 and plasma cell myeloma: The diagnosis of MM following the International Myeloma Working Group (IMWG) criteria, requiring ≥10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB features (hypercalcemia, renal failure, anemia, bone lesions), specific biomarkers such as ≥60% monoclonal plasma cells, serum-free light chain ratio ≥100, and multiple localized lesions on magnetic resonance imaging (MRI) [4].